COX-2 and the kidneys

Area of Science:

• Nephrology
• Pharmacology
• Biochemistry

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) frequently cause kidney adverse effects.
• NSAID-induced renal dysfunction involves cyclooxygenase (COX) inhibition, impacting renal blood flow (RBF) and glomerular filtration rate (GFR).
• The discovery of COX-1 and COX-2 isoenzymes led to developing selective COX-2 inhibitors, aiming to reduce NSAID toxicity.

Purpose of the Study:

• To evaluate the renal safety profile of preferential and specific COX-2 inhibitors compared to conventional NSAIDs.
• To investigate the distinct roles of COX-1 and COX-2 in kidney function and NSAID-related nephrotoxicity.
• To determine if COX-2 inhibitors offer significant advantages in preventing renal side effects.

Main Methods:

• Review of animal experiments and clinical trials involving NSAIDs and COX-2 inhibitors.
• Analysis of the literature on the expression and function of COX-1 and COX-2 in the kidney.
• Assessment of renal side effects such as RBF reduction, GFR changes, sodium/water retention, hyperkalemia, and water intoxication.

Main Results:

• COX-2 is constitutively expressed in the kidney and plays a key role in sodium excretion, renin release, and antidiuretic hormone antagonism.
• Evidence suggests COX-1 is predominant for maintaining renal hemodynamics, though further research is needed.
• Preferential and specific COX-2 inhibitors provide minimal to negligible renal safety benefits regarding sodium retention, hyperkalemia, and water intoxication.

Conclusions:

• The distinction between "physiologic" COX-1 and "inflammatory" COX-2 is not clear-cut in the kidney.
• COX-2 inhibitors offer limited advantages in preventing common NSAID-induced renal adverse effects.
• Precautions similar to those for conventional NSAIDs are still necessary when using COX-2 inhibitors due to potential renal risks.